Everyone is entitiled to voice an opinion which is why we all say to DYOR
The best research you can do in my opinion is on the company and the management team

So lets look at their history (information taken from https://**.st)

It looks like there is a lot of experience with the team from Business to Science

Vince Ippolito

Position MD, President & Executive Chairman

Profile

Mr. Vincent P. Ippolito, also known as Vince, serves as the President of Botanix Pharmaceuticals Limited since May 20, 2019 and Executive Chairman since July 18, 2019. Mr. Ippolito is Acting Managing Director of Botanix Pharmaceuticals Limited since 2019. He served as Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, Inc. since March 2014 until September 2017. Mr. Ippolito has over 30 years of experience leading specialty medical sales and marketing efforts at Valeant Pharmaceuticals, Inc. (Valeant), Medicis Pharmaceutical Corporation (Medicis) and Novartis AG. Mr. Ippolito served as Senior Vice President and General Manager of Aesthetics at Valeant Pharmaceuticals International, Inc. since December 11, 2012. Mr. Ippolito served as Chief Commercial Officer and Executive Vice President of Sales and Marketing at Medicis Pharmaceutical Corporation from April 2008 to December 2012. Mr. Ippolito joined Medicis in 2003 and served as Senior Vice President of North American Sales from January 2006 to April 1, 2008. Mr. Ippolito served as General Manager of Dermatology products, where he was responsible for the marketing and sales functions from 2003 to 2006. In his tenure at Medicis, he helped launch more than ten new products, including LOPROX(R) Shampoo, VANOS(R), RESTYLANE(R), PERLANE(R), SOLODYN(R), and ZIANA(R). Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine. He served Novartis AG from 1986 to January 2003, where he served in a variety of sales and marketing roles, including General Manager, Marketing Group Brand Leader for Dermatology and Bone Products, where he led the re-launch of Lamisil(R), and Vice President of Sales in the Respiratory and Dermatology Division, where he oversaw the launch of four new products including Elidel(R). He has been Director at Suneva Medical, Inc. since August 24, 2017. He most recently served as President and Chief Operating Officer of Dermavant Sciences. Mr. Ippolito holds a B.A. in Business Administration, Management and Operations from the University of Wisconsin and a minor in East Asian Studies from Sophia University in Japan.

Michael Thurn

Position COO& Executive Director

Profile

Dr.Michael Thurn, Ph.D. has been Chief Operating Officer of BotanixPharmaceuticals Limited since February 14, 2017 and has been its ExecutiveDirector since Feb 12, 2019. Dr. Thurn has been Chief Operating Officer ofTelesso Technologies Limited since October 11, 2013. Dr. Thurn served as theChief Executive Officer of Mimetica Pty Limited since September 2006 andsuccessfully guided a melancortin -5 receptor targeting drug from pre-clinicaltesting through completion of a Phase 2 clinical trial. For over 10 years, Dr.Thurn has been responsible for 4 IND-enabling programs and been involved in thepreclinical evaluation of over 12 drugs and vaccines for registration inAustralia. He served as the Managing Director of Spinifex Pharmaceuticals PtyLtd., and Chief Operating Officer at Cytopia Research Pty Ltd. He served asHead of Drug Development at Xenome Ltd., Anti-cancer Team Leader at NovogenLtd., and Senior Toxicologist at the Therapeutic Goods Administration (TGA).Dr.Thurn has uniqu eexperience in drug development, having led development of atopical treatment for acne being developed by venture capital backed companyMimetica. Dr. Thurn obtained his Ph.D in Immunology and Biochemistry from theUniversity of Technology, Sydney in 1994.

Bill Bosch

Position ChiefScientific Officer & Executive Director

Profile

Dr. HenryWilliam Bosch, also known as Bill, BA, PhD serves as the Chief ScientificOfficer of iCeutica Inc. Dr. Bosch has been an Executive Director of BotanixPharmaceuticals Limited since July 1, 2016 and also serves as Chief ScientificOfficer. He served as an Executive Director at Bone Medical Ltd. since July 1,2016. He is a seasoned Pharmaceuticals executive with more than 25 years ofexperience in the industry, focusing on applications of drug deliverytechnology to Pharmaceuticals product development. Dr. Bosch served as Directorof Research & Development at iCeutica Inc. since September 17, 2007. Dr.Bosch co-founded NanoSystems LLC in 1995. He served as Director ofPharmaceutical Research of Elan Corp., where he managed the developmentactivities for four commercial products that incorporate nanotechnology. He isa co-inventor of the SoluMatrixTM technology and has been instrumental in thedevelopment and scale up of the platform and the development of the three FDAapproved products that use that drug delivery technology. He was a co-inventorof NanoCrystal Technology. Dr. Bosch has earned a Ph.D.

Matt Callahan

Position ExecutiveDirector

Profile

Mr.Matthew Callahan, also known as Matt, MBA, LLB serves as Director at OrthocellLimited since February 10, 2020. He served as a Non-Executive Director ofOrthocell Limited from May 30, 2006 to August 23, 2019. He served as CorporateAdviser of Orthocell Limited since August 23, 2019 until February 10, 2020. Heserves as Executive Director at Botanix Pharmaceuticals Limited since February2020. He Founded Botanix Pharmaceuticals Ltd. He is a Co-Founder and InvestmentDirector of Stone Ridge Ventures. He serves as Non-Executive Director atEmerald Clinics Limited since March 19, 2018. Mr. Callahan is the foundingChief Executive Officer and President of iCeutica Inc and ChurchillPharmaceuticals Inc. He is a co-inventor of some of the technologies thatcomprise the SoluMatrix Fine Particle Technology drug delivery platform thatiCeutica uses to develop new Pharmaceuticals. Mr. Callahan served as anInvestment Manager at Foundation Capital. He has legal, IP and investmentmanagement experience. He served as the Chief Executive Officer of DimerixLimited. Mr. Callahan was the Chief Executive Officer at Cortec Systems PtyLtd. He served as the General Manager at Nearmap Ltd., and also served as itsGeneral Counsel until September 30, 2005. Mr. Callahan served as SeniorAssociate with a National legal firm. Mr. Callahan has worked as an investmentdirector for two venture capital firms investing in life sciences, cleantechnology and other sectors and was General Manager and General Counsel withAustralian listed technology and licensing company ipernica Ltd, where he wasresponsible for the licensing programs that generated more than $120M inrevenue. Mr. Callahan served as an Executive Director of BotanixPharmaceuticals Ltd. from July 1, 2016 to August 23, 2019. He serves as aDirector of Glycan Bioscience LLC. He served as Non-Executive Director ofIntellection Holdings Pty Ltd., and iCeutica Inc. He served as a Director ofDimerix Limited and Luceo Systems. Mr. Callahan serves as Founding Chairman ofWA chapter of Founders Forum and serves as member of the Licensing ExecutivesSociety of Australia and AVCAL. Mr. Callahan is regular participant in theEntrepreneurship and Venture Capital programs at the Graduate School ofManagement (UWA). In 2002, He was awarded an inaugural Business News '40 under40' award recognizing the next generation of business leaders. He served asExecutive Director at Botanix Pharmaceuticals Limited from July 1, 2016 tillAugust 23, 2019. Mr. Callahan holds a L. L. B. degree with Honors and an M. B.A. degree from The University of Western Australia.

Stephane Levy

Position ChiefMedical Officer

Profile

Dr.Stephane Levy has been Chief Medical Officer of Botanix Pharmaceuticals Ltdsince July 7, 2018. Dr. Levy was Vice President of Research & Development -US Operations at Aqua Pharmaceuticals, LLC since February 14, 2017. He wasresponsible for the leadership and management of Aqua Pharmaceuticals' U.S.Research and Product Development organization including all aspects of projectmanagement, clinical development, chemistry, manufacturing & controls,toxicology, regulatory affairs, medical affairs and quality assurance. He isOverseeing the development of all new drug and device products for the U.S.market, he is lead a team to develop, implement and coordinate productlifecycle infrastructure, ensuring the consistent manufacturing of safe andeffective products. Before joining Aqua Pharmaceuticals, Dr. Levy served asVice President and Medical Unit Head of Immunology & Dermatology atNovartis U.S. Throughout his more than 20 years of experience in clinicaldevelopment, he has also held executive roles at Genzyme and Sanofi.

Ric Peterson

Position ChiefFinancial Officer

Profile

Mr.Richard D. Peterson, also known as Ric, serves as Chief Financial Officer atBotanix Pharmaceuticals Limited since August 9, 2019. Mr. Peterson served asChief Financial Officer of Sienna Biopharmaceuticals, Inc. since March 24, 2017until March 29, 2018. Mr. Peterson is a director on the Board of UniversalInsurance Holdings (NYSE: UVE). Mr. Peterson has experience in the areas ofexecutive management, finance and accounting. He served as the Chief FinancialOfficer of Novan, Inc., from September 2015 to March 22, 2017. He wasresponsible for financial operations, investor relations and other corporatefunctions at Novan. He leads Novan's newly focused commercialization effortsincluding sales, marketing and managed care for its dermatology products. MrPeterson has extensive experience in the dermatology industry and held theposition of Chief Financial Officer at Dermavant Sciences. He served as theChief Financial Officer, Executive Vice President and Treasurer of MedicisTechnologies Corporation. He served as the Chief Financial Officer, ExecutiveVice President and Treasurer of Medicis Pharmaceutical Corporation from 1995 toDecember 22, 2012 and served as its Chief Accounting Officer until December 22,2012. He joined Medicis in 1995 and served as its Senior Vice President ofFinance from February 2007 to April 1, 2008 and Vice President of Finance fromAugust 2002 to February 2007. Prior to joining Medicis, he was a SeniorFinancial Auditor and Consultant at PricewaterhouseCoopers LLP from 1992 to1995. He has been an Independent Director at Universal Insurance Holdings, Inc.since 2014. He is a Member of the Financial Executives Institute and serves onthe board of the Phoenix Zoo, a non-profit organization. He received Bachelorof Science in Accounting from Arizona State University-Tempe in 1992.

Howie McKibbon

Position ChiefCommercial Officer

Profile

Mr. HowieMcKibbon serves as Chief Commercial Officer at Botanix Pharmaceuticals Limitedsince August 9, 2019. He recently served as Senior Vice President (SVP),Worldwide Commercial Operations, at Dermavant Sciences with responsibility forall commercial activity. Prior to Dermavant Sciences, he was SVP, Sales andMarketing, at Anacor Pharmaceuticals, where he built the sales, marketing andmanaged markets functions. Prior to Anacor Pharmaceuticals, he was VP,Dermatology and Immunology, at Medicis Pharmaceuticals. He also held commercialleadership positions for neuroscience and oncology brands from development toexclusivity at Cephalon and Wyeth. Mr McKibbon has launched 15 productsincluding 11 in dermatology. He has managed over 30 dermatology products.

Simon Robertson

Position CompanySecretary

Profile

Mr. SimonRobertson, B.Bus, M Appl. Fin, CA, serves as Company Secretary at EmeraldClinics Limited. He has been Company Secretary of Botanix PharmaceuticalsLimited since February 17, 2017. Mr. Robertson has experience in corporatefinance, accounting and administration, capital raisings and ASX compliance andregulatory requirements. He is a member of the Institute of CharteredAccountants and the Governance Institute of Australia. Mr. Robertson gained aBachelor of Business from Curtin University in Western Australia and Master ofApplied Finance from Macquarie University in New South Wales.

DYOR